EBMT 2023 | The evolution of autoSCT outcomes for R/R Hodgkin lymphoma
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, gives an overview of the improvements made in autologous stem cell transplantation (autoSCT) for relapsed/refractory (R/R) Hodgkin lymphoma. Dr Sureda comments on how autoSCT outcomes have improved by implementing salvage therapies and PET-CT before transplantation, and consolidation strategies after transplant in patients at risk of relapse. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Autologous stem cell transplantation is still nowadays the standard of care for those patients with classical Hodgkin’s lymphoma that are primary refractory to first line therapy, or that relapse after achieving first complete remission after first line therapy. In the last few years, we have been able to improve the results of autologous stem cell transplantation in this setting by the introduction of new drugs being used in salvage strategy before transplant...
Autologous stem cell transplantation is still nowadays the standard of care for those patients with classical Hodgkin’s lymphoma that are primary refractory to first line therapy, or that relapse after achieving first complete remission after first line therapy. In the last few years, we have been able to improve the results of autologous stem cell transplantation in this setting by the introduction of new drugs being used in salvage strategy before transplant. By introducing PET-CT to evaluate disease status before autologous stem cell transplantation, also by introducing consolidation strategies with new drugs after the autologous stem cell transplantation setting in patients that have a high relapse risk after the transplant, and maybe in the near future, we will be able to select specific subgroups of patients in which or in whom autologous stem cell transplantation could eventually be escaped and patients being consolidated with new drugs such as brentuximab vedotin of checkpoint inhibitors.
Read more...
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
